Clinical Trial Detail

NCT ID NCT01781572
Title A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Novartis
Indications

melanoma

Therapies

Binimetinib + Ribociclib

Age Groups: adult

Additional content available in CKB BOOST